Predicine is pleased to announce the latest publication on breast cancer in Frontiers in Oncology. View the publication: https://t.co/ie43jQRG5M For additional information about Predicine and our biopharma solutions, click below: https://t.co/JOwLL6U9Eu
Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients https://t.co/3pcM5jgGrb https://t.co/irGmwAyqxn
New research: Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients: Background Poor outcomes have been widely reported… #oncology htt
Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients. #MBC #bcsm #clinicaltrials #metastatic #breastcancer https://t.co/wDaLMMMz0V